Efficacy and Safety of Liraglutide Added to Insulin Treatment in Type 1 Diabetes: The ADJUNCT ONE Treat-To-Target Randomized Trial
The DOI matches its Crossref record; 26 of the 26 references it cites were found in a registry or an index.
Abstract
OBJECTIVE: To investigate whether liraglutide added to treat-to-target insulin improves glycemic control and reduces insulin requirements and body weight in subjects with type 1 diabetes. RESEARCH DESIGN AND METHODS: A 52-week, double-blind, treat-to-target trial involving 1,398 adults randomized 3:1 to receive once-daily subcutaneous injections of liraglutide (1.8, 1.2, or 0.6 mg) or placebo added to insulin. RESULTS: HbA1c level was reduced 0.34–0.54% (3.7–5.9 mmol/mol) from a mean baseline of 8.2% (66 mmol/mol), and significantly more for liraglutide 1.8 and 1.2 mg compared with placebo (estimated treatment differences [ETDs]: 1.8 mg liraglutide −0.20% [95% CI −0.32; −0.07]; 1.2 mg liraglutide −0.15% [95% CI −0.27; −0.03]; 0.6 mg liraglutide −0.09% [95% CI −0.21; 0.03]). Insulin doses were reduced by the addition of liraglutide 1.8 and 1.2 mg versus placebo (estimated treatment ratios: 1.8 mg liraglutide 0.92 [95% CI 0.88; 0.96]; 1.2 mg liraglutide 0.95 [95% CI 0.91; 0.99]; 0.6 mg liraglutide 1.00 [95% CI 0.96; 1.04]). Mean body weight was significantly reduced in all liraglutide groups compared with placebo ETDs (1.8 mg liraglutide −4.9 kg [95% CI −5.7; −4.2]; 1.2 mg liraglutide −3.6 kg [95% CI −4.3; −2.8]; 0.6 mg liraglutide −2.2 kg [95% CI −2.9; −1.5]). The rate of symptomatic hypoglycemia increased in all liraglutide groups (estimated rate ratios: 1.8 mg liraglutide 1.31 [95% CI 1.07; 1.59]; 1.2 mg liraglutide 1.27 [95% CI 1.03; 1.55]; 0.6 mg liraglutide 1.17 [95% CI 0.97; 1.43]), and hyperglycemia with ketosis increased significantly for liraglutide 1.8 mg only (event rate ratio 2.22 [95% CI 1.13; 4.34]). CONCLUSIONS: Liraglutide added to insulin therapy reduced HbA1c levels, total insulin dose, and body weight in a population that was generally representative of subjects with type 1 diabetes, accompanied by increased rates of symptomatic hypoglycemia and hyperglycemia with ketosis, thereby limiting clinical use in this group.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The largest clinical trials of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) in type 1 diabetes have been conducted with liraglutide 1.8 mg daily, and results showed modest A1C reductions ($0.4%), decreases in weight ($5 kg), and reductions in insulin doses (71,72).”
From 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes—2025 (2025) · cites this paper as [71]
In the citing paper
“However, increased rates of hypoglycemia and ketosis were shown.”
In the citing paper
“The largest clinical trials in people with type 1 diabetes were conducted with liraglutide and showed decreases in HbA 1c at daily doses of 1.8 mg (0.2-0.4% [2-4 mmol/mol]), decreases in weight (5 kg), and reductions in insulin doses (257,258).”
In the citing paper
“GLP1 receptor agonists reduce bodyweight and insulin dose, with modest improvements in glycaemic control.[93][94][95][96]”
From The future of type 1 diabetes therapy (2025) · cites this paper as [93]
In the citing paper
“Adding SGLT2 inhibitors at a lower than usual dose to insulin therapy in T1DM may reduce glucose variability and facilitate glucose control, thereby reducing insulin doses and hypoglycaemia.803”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [803]
Citations
Cites
Hyperglycemic crises in adult patients with diabetes
Kitabchi, A. E., Umpierrez, G. E., Miles, J. M., & Fisher, J. N. (2009) · Diabetes Care · doi:10.2337/dc09-9032 · Cited by 2,062
Seaquist, E. R., Anderson, J., Childs, B., Cryer, P., Dagogo-Jack, S., Fish, L., Heller, S. R., Rodriguez, H., Rosenzweig, J., & Vigersky, R. (2013) · Diabetes Care · doi:10.2337/dc12-2480 · Cited by 1,389 · cited 3×
“****EAC-confirmed malignant neoplasms were all skin cancers (two malignant melanomas; one basal cell carcinoma) using ADA classification of hypoglycemia (13).”
BackgroundMethodInfluentialMiller, K. M., Foster, N. C., Beck, R. W., Bergenstal, R. M., DuBose, S. N., DiMeglio, L. A., Maahs, D. M., & Tamborlane, W. V. (2015) · Diabetes Care · doi:10.2337/dc15-0078 · Cited by 1,254
Rosenstock, J., & Ferrannini, E. (2015) · Diabetes Care · doi:10.2337/dc15-1380 · Cited by 664 · cited 1×
“drate levels may be reduced as a result of urinary excretion (23,24).”
BackgroundWeinstock, R. S., Xing, D., Maahs, D. M., Michels, A., Rickels, M. R., Peters, A. L., Bergenstal, R. M., Harris, B., DuBose, S. N., Miller, K. M., et al. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1589 · Cited by 338
Sun, F., Wu, S., Guo, S., Yu, K., Yang, Z., Li, L., Zhang, Y., Quan, X., Ji, L., & Zhan, S. (2015) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2015.07.015 · Cited by 304
Implementation of Treatment Protocols in the Diabetes Control and Complications Trial
Diabetes Control and Complications Trial Research Group (1995) · Diabetes Care · doi:10.2337/diacare.18.3.361 · Cited by 283
Purnell, J. Q., Zinman, B., & Brunzell, J. D. (2013) · Circulation · doi:10.1161/circulationaha.111.077487 · Cited by 267
Self-citationDejgaard, T. F., Frandsen, C. S., Hansen, T. S., Almdal, T., Urhammer, S., Pedersen-Bjergaard, U., Jensen, T., Jensen, A. K., Holst, J. J., Tarnow, L., et al. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00436-2 · Cited by 179
Jones, A. G., McDonald, T. J., Shields, B. M., Hill, A. V., Hyde, C. J., Knight, B. A., & Hattersley, A. T. (2016) · Diabetes Care · doi:10.2337/dc15-0258 · Cited by 178
Cited by
Items 101–200 of 347
Halperin, I. J., Wicklow, B., Amed, S., Chambers, A., Courage, C., Cummings, E., Kirkland, P., MacKay, D., Nakhla, M., Punthakee, Z., et al. (2025) · Canadian Journal of Diabetes · doi:10.1016/j.jcjd.2025.01.001 · Cited by 22
Bomholt, T., Idorn, T., Knop, F. K., Jørgensen, M. B., Ranjan, A. G., Resuli, M., Hansen, P. M., Borg, R., Persson, F., Feldt‐Rasmussen, B., et al. (2020) · The Nephron journals/Nephron journals · doi:10.1159/000510613 · Cited by 26
Longwell, C. K., Hanna, S., Hartrampf, N., Sperberg, R. A. P., Huang, P., Pentelute, B. L., & Cochran, J. R. (2020) · ACS Chemical Biology · doi:10.1021/acschembio.0c00722 · Cited by 22
Effectiveness and Safety of GLP-1 Receptor Agonists in Patients with Type 1 Diabetes
Almohareb, S. N., Alfayez, O. M., Aljuaid, S. S., Alshahrani, W. A., Bakhsh, G. H., Alshammari, M. K., Yami, M. S. A., Alshaya, O. A., Alomran, A. S., Korayem, G. B., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13216532 · Cited by 25
Huang, Y., Jiang, Z., & Wei, Y. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.9813 · Cited by 25
Johansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Hartmann, B., Holst, J. J., Vilsbøll, T., Andersen, H. U., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14568 · Cited by 23
Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
Resnick, O., Bril, F., & Beauchamp, G. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1520313 · Cited by 25
Therapeutic strategies targeting mechanisms of macrophages in diabetic heart disease
Zhang, C., Shi, Y., Liu, C., Sudesh, S. M., Zhao, H., Li, P., Liu, Q., Ma, Y., Shi, A., & Cai, H. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02273-4 · Cited by 32
Pharmacologic treatment options for type 1 diabetes: what’s new?
Nally, L. M., Sherr, J. L., Name, M. A. V., Patel, A., & Tamborlane, W. V. (2019) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2019.1597705 · Cited by 26
SGLT inhibition: a possible adjunctive treatment for type 1 diabetes
Aktürk, H. K., Rewers, A. H., & Garg, S. K. (2018) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000423 · Cited by 21
Ito, A., Horie, I., Miwa, M., Sako, A., Niri, T., Nakashima, Y., Shigeno, R., Haraguchi, A., Natsuda, S., Akazawa, S., et al. (2020) · Journal of Diabetes Investigation · doi:10.1111/jdi.13486 · Cited by 20
New Horizons: Emerging Antidiabetic Medications
Mingrone, G., Castagneto‐Gissey, L., & Bornstein, S. R. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac499 · Cited by 22
Al‐Ozairi, E., Irshad, M., Taghadom, E., SOJAN, L. G., Kandari, J. A., Alroudhan, D., & le Roux, C. W. (2023) · Obesity · doi:10.1002/oby.23677 · Cited by 21
Treating obesity in type 1 diabetes mellitus – review of efficacy and safety
Freeby, M., & Lane, K. L. (2023) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000841 · Cited by 23
Therapeutic approaches for latent autoimmune diabetes in adults: One size does not fit all
Koufakis, T., Katsiki, N., Zebekakis, P. E., Dimitriadis, G., & Kotsa, K. (2019) · Journal of Diabetes · doi:10.1111/1753-0407.12982 · Cited by 20
Adjunct therapies in treatment of type 1 diabetes
Goyal, I., Sattar, A., Johnson, M., & Dandona, P. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13078 · Cited by 18
Breaking and restoring immune tolerance to pancreatic beta-cells in type 1 diabetes
Erdem, N., Montero, E., & Roep, B. O. (2021) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000646 · Cited by 19
Mazzotta, F. A., Paoli, L. L., Rizzi, A., Tartaglione, L., Leo, M. L., Popolla, V., Barberio, A., Viti, L., Leo, M. A. S. D., Pontecorvi, A., et al. (2024) · Nutrition and Diabetes · doi:10.1038/s41387-024-00319-w · Cited by 30
Wang, W., Gao, Y., Chen, D., Wang, C., Feng, X., & Ran, X. (2017) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2017.05.007 · Cited by 19
Dysfunctional β-cell autophagy induces β-cell stress and enhances islet immunogenicity
Austin, M. C., Muralidharan, C., Roy, S., Crowder, J. J., Piganelli, J. D., & Linnemann, A. K. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1504583 · Cited by 19
Cengiz, E., Danne, T., Ahmad, T., Ayyavoo, A., Beran, D., Codner, E., Ehtisham, S., Jarosz-Chobot, P., Mungai, L. N. W., Ng, S. M., et al. (2025) · Hormone Research in Paediatrics · doi:10.1159/000543169 · Cited by 17
GLP-1 receptor agonist–induced diabetic ketoacidosis: A case report
Zhang, J., Ma, Y., Zu, Q., Wang, X., & Zhang, Y. (2024) · Medicine · doi:10.1097/md.0000000000039799 · Cited by 18
Kuhadiya, N. D., Prohaska, B. D., Ghanim, H., & Dandona, P. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13609 · Cited by 19
Empagliflozin in type 1 diabetes
Mathieu, C., den Mooter, L. V., & Eeckhout, B. (2019) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s194688 · Cited by 17
Self-citationInfante, M., Silvestri, F., Padilla, N., Pacifici, F., Pastore, D., Pinheiro, M. M., Caprio, M., Tesauro, M., Fabbri, A., Novelli, G., et al. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041303 · Cited by 20
Overweight and Obesity in Adults with Type 1 Diabetes: A Growing Challenge
Majanović, S. K., Detel, D., Igrec, M., Bergoč, A., Rahelić, V., & Rahelić, D. (2024) · Diabetology · doi:10.3390/diabetology5030018 · Cited by 22
Recent update on biological activities and pharmacological actions of liraglutide
Tiwari, J., Gupta, G., Dahiya, R., Pabreja, K., Sharma, R. K., Mishra, A., & Dua, K. (2017) · EXCLI journal · doi:10.17179/excli2017-323 · Cited by 17
Non-insulin pharmacological therapies for treating type 1 diabetes
Frandsen, C. S., Dejgaard, T. F., Madsbad, S., & Holst, J. J. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1483339 · Cited by 18
Doggrell, S. A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1519547 · Cited by 16
Cardiovascular risk management in type 1 diabetes
Teoh, I. H., Elisaus, P., & Schofield, J. D. (2021) · Current Diabetes Reports · doi:10.1007/s11892-021-01400-9 · Cited by 15
Xu, Y., Echouffo Tcheugui, J. B., Coresh, J., Grams, M. E., Selvin, E., Fang, M., & Shin, J. (2025) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.16300 · Cited by 15
XU, Y., Malek, N. D., Chang, A. R., Echouffo-Tcheugui, J. B., Selvin, E., Grams, M. E., Fang, M., & Shin, J. (2026) · Nature Medicine · doi:10.1038/s41591-026-04274-0 · Cited by 22
Strategically Playing with Fire: SGLT Inhibitors as Possible Adjunct to Closed-Loop Insulin Therapy
Pasqua, M., Tsoukas, M. A., & Haidar, A. (2021) · Journal of Diabetes Science and Technology · doi:10.1177/19322968211035411 · Cited by 18
Potential New Therapeutic Implications of Semaglutide: New Colours of the Rainbow?
Gouveri, E., Popovic, D. S., & Παπάνας, Ν. (2023) · Diabetes Therapy · doi:10.1007/s13300-023-01506-1 · Cited by 16
Karakasis, P., Koufakis, T., Patoulias, D., Barkas, F., Klisic, A. N., Mitrović, M., Doumas, M. N., Παπάνας, Ν., & Popovic, D. S. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15979 · Cited by 20
Type 1 Diabetes: Disease Stratification
Insel, R. A., Dutta, S., & Hedrick, J. A. (2017) · Biomedicine Hub · doi:10.1159/000481131 · Cited by 18
Albèr, A., Brønden, A., & Knop, F. K. (2017) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12911 · Cited by 15
Double Diabetes: A Growing Problem Requiring Solutions
Popovic, D. S., & Παπάνας, Ν. (2021) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/a-1392-0590 · Cited by 14
Recent developments in adjunct therapies for type 1 diabetes
Timmons, J. G., Littlejohn, L., Boyle, J. G., & Petrie, J. R. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2159806 · Cited by 17
RSSDI consensus recommendations on insulin therapy in the management of diabetes
(extended), E. P., Chawla, R., Makkar, B. M., Aggarwal, S., Bajaj, S., Das, A. K., Ghosh, S. K., Gupta, A., Gupta, S., Jaggi, S., et al. (2019) · International Journal of Diabetes in Developing Countries · doi:10.1007/s13410-019-00783-6 · Cited by 16
Al‐Ozairi, E., Irshad, M., Alkandari, J., SOJAN, L. G., Alroudhan, D., Alotaibi, N., & le Roux, C. W. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70172 · Cited by 14
Thivolet, C. H., Larger, É., Cariou, B., Renard, É., Hanaire, H. P., Benhamou, P., Guerci, B., Mathiotte, É., & Chikh, K. (2023) · Diabetes & Metabolism · doi:10.1016/j.diabet.2023.101433 · Cited by 13
Edwards, K., Uruska, A. A., Duda‐Sobczak, A., Zozulińska‐Ziółkiewicz, D., & Lingvay, I. (2023) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188231180987 · Cited by 15
Frampton, R., SNAITH, J. R., HOCKING, S. L., Holmes-Walker, D. J., Olsen, N., & Greenfield, J. R. (2024) · Diabetic Medicine · doi:10.1111/dme.15377 · Cited by 15
Johansen, N. J., Dejgaard, T. F., Lund, A., Schlüntz, C., Larsen, E. L., Poulsen, H. E., Goetze, J. P., Møller, H. J., Vilsbøll, T., Andersen, H. U., et al. (2020) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14078 · Cited by 14
Incretins beyond type 2 diabetes
Mathieu, C., & Ahmadzai, I. (2023) · Diabetologia · doi:10.1007/s00125-023-05980-x · Cited by 17
Self-citationCebada, A. B., Nattero‐Chávez, L., Díaz, S. A., Escobar-Morreale, H. F., & Luque‐Ramírez, M. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.0316 · Cited by 13
STOUGAARD, E. B., Andersen, M. R., Bagger, J. I., Søndergaard, E., Østergaard, J. A., Curovic, V. R., Persson, F., Almdal, T., Mathiesen, A. S., Andries, A., et al. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.16606 · Cited by 14
Pharmacological therapies to address obesity in type 1 diabetes
Casu, A., Bilal, A., & Pratley, R. E. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000555 · Cited by 16
Fano, M. D., Porcellati, F., Fanelli, C. G., Corio, S., Mazzieri, A., Lucidi, P., Bolli, G. B., & Bassotti, G. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110828 · Cited by 15
Nassar, M., Chaudhuri, A., Ghanim, H., & Dandona, P. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i2.133 · Cited by 14
An adipocentric perspective of pancreatic lipotoxicity in diabetes pathogenesis
Risi, R., Vidal‐Puig, A., & Bidault, G. (2024) · Journal of Endocrinology · doi:10.1530/joe-23-0313 · Cited by 19
Incretins: B eyond type 2 diabetes
Dandona, P., Ghanim, H., & Chaudhuri, A. (2018) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13153 · Cited by 14
Beyond type 2 diabetes: sodium glucose co‐transporter‐inhibition in type 1 diabetes
Biester, T., Kordonouri, O., & Danne, T. (2019) · Diabetes Obesity and Metabolism · doi:10.1111/dom.13659 · Cited by 13
Holmager, P., Christensen, M. B., Nørgaard, K., & Schmidt, S. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241289438 · Cited by 14
Alternative therapeutic strategies in diabetes management
Annicchiarico, A., Barile, B., Buccoliero, C., Nicchia, G. P., & Brunetti, G. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i6.1142 · Cited by 14
Lin, C., Cai, X., Yang, W., Lv, F., Nie, L., & Ji, L. (2020) · BMC Medicine · doi:10.1186/s12916-020-01787-4 · Cited by 12
Abu‐Zaid, A., Altowairqi, A. K., Dissanayaka, T. D., Oganesyan, A., Bhagavathula, A. S., Alhabeeb, H., Baradhwan, A., Alomar, S. A., & Tom, S. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105456 · Cited by 12
SGLT2 inhibitors in type 1 diabetes: knocked down, but up again?
Petrie, J. R. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30315-7 · Cited by 12
Liraglutide-Induced Weight Loss May be Affected by Autonomic Regulation in Type 1 Diabetes
Hansen, C. S., Frandsen, C. S., Fleischer, J., Vistisen, D., Holst, J. J., Tarnow, L., Knop, F. K., Madsbad, S., Andersen, H. U., & Dejgaard, T. F. (2019) · Frontiers in Endocrinology · doi:10.3389/fendo.2019.00242 · Cited by 11
Drawing lines in the sand: The growing threat of obesity in type 1 diabetes
Koufakis, T., Patoulias, D., Zografou, I., Papanas, N., & Popovic, D. S. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v15.i5.823 · Cited by 10
Purcell, A. R., Zhen, X. M., Wong, J., & Glastras, S. J. (2025) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70188 · Cited by 13
Ballav, C., Dhere, A., Kennedy, I., Agbaje, O. F., White, S. J., Franklin, R. H., Hartmann, B., Holst, J. J., Holman, R. R., & Owen, K. R. (2020) · Endocrinology Diabetes & Metabolism · doi:10.1002/edm2.130 · Cited by 10
Klein, K. R., BOEDER, S. C., Freeman, J. L. R., Dunn, I. M., Dvergsten, C., Madduri, S. S., Giovannetti, E. R., Valcarce, C., Buse, J. B., & Pettus, J. (2022) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14697 · Cited by 11
SGLT inhibitors for people with type 1 diabetes
Llano, A., McKay, G., & Fisher, M. (2019) · Practical Diabetes · doi:10.1002/pdi.2222 · Cited by 10
Adjunctive therapies in type 1 diabetes mellitus
Lane, K. L., & Freeby, M. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000602 · Cited by 12
Shah, V. N., Agesen, R. M., Bardtrum, L., Christiansen, E., SNAITH, J. R., & Greenfield, J. R. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241305647 · Cited by 11
Self-citationSu, B., Luan, Z., Liu, H., Tuomilehto, J. O., & Ji, X. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1571247 · Cited by 13
Moiz, A., Peters, T. M., Tsoukas, M. A., Yu, O. H. Y., Filion, K. B., & Eisenberg, M. J. (2026) · EClinicalMedicine · doi:10.1016/j.eclinm.2026.103991 · Cited by 14
Aberer, F., Pieber, T. R., Eckstein, M. L., Sourij, H., & Moser, O. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061180 · Cited by 12
Zenz, S., Regittnig, W., Boulgaropoulos, B., Augustin, T., Brunner, M., Korsatko, S., Münzker, J., Narath, S. H., Raml, R., Magnes, C., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac369 · Cited by 11
Hirsch, I. B., Parkin, C. G., Cavaiola, T. S., & Bergenstal, R. M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15883 · Cited by 8
Seetharaman, S., & Cengiz, E. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241305641 · Cited by 9
Pharmacologic adjunctive to insulin therapies in type 1 diabetes: The journey has just begun
Karras, S. Ν., Koufakis, T., Zebekakis, P. E., & Kotsa, K. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i4.234 · Cited by 9
Koufakis, T., Vas, P. R. J., & Kotsa, K. (2020) · Diabetic Medicine · doi:10.1111/dme.14496 · Cited by 11
Diabetes Technology and Therapy in the Pediatric Age Group
Maahs, D. M., Lal, R., & Shalitin, S. (2019) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2019.2510 · Cited by 9
Ang, K. H., & Sherr, J. L. (2017) · Expert Opinion on Drug Delivery · doi:10.1080/17425247.2017.1360862 · Cited by 11
Adjunct Antihyperglycemic Agents in Overweight and Obese Adults With Type 1 Diabetes
Isaacs, D. M., Yager, S., Parker, M., Wolfe, L., Luxenburg, J., & Lekic, S. (2018) · Annals of Pharmacotherapy · doi:10.1177/1060028018816728 · Cited by 10
Seetharaman, S., & Cengiz, E. (2024) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241309896 · Cited by 9
STOUGAARD, E. B., Curovic, V. R., & Hansen, T. W. (2025) · Diabetes Therapy · doi:10.1007/s13300-025-01726-7 · Cited by 11
The effects of GLP-1 agonists on HbA1c and insulin dose among patients with type 1 diabetes
Alhowiti, A., & Mirghani, H. O. (2025) · Frontiers in Endocrinology · doi:10.3389/fendo.2025.1550938 · Cited by 10
Jafar, A., & Pasqua, M. (2024) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15463 · Cited by 11
Treatment with GLP-1 Receptor Agonists
Madsbad, S., & Holst, J. J. (2018) · Endocrinology · doi:10.1007/978-3-319-27317-4_20-1 · Cited by 9
Fallatah, W., Brema, I. A., Alobedallah, A., Alkhathami, R., Zaheer, S., Almalki, E., Almehthel, M. S., ALZAHRANI, S. H., & Almalki, M. (2022) · Avicenna Journal of Medicine · doi:10.1055/s-0041-1742196 · Cited by 8
Lamaro, B. D., Greenfield, J. R., & SNAITH, J. R. (2024) · Journal of Patient Experience · doi:10.1177/23743735241257811 · Cited by 10
Mertens, J., Winter, H. T. D., Dirinck, E. L., Francque, S., & Block, C. E. M. D. (2025) · Diabetes Technology & Therapeutics · doi:10.1177/15209156251362497 · Cited by 12
Joy, B., Ramsamooj, A., Ibrahim, S., Wen, J., Hsu, N., & Frezza, E. (2026) · Endocrine · doi:10.1007/s12020-025-04494-3 · Cited by 13
Dapagliflozin for the treatment of type 1 diabetes mellitus
Pafili, K., Maltezos, E. S., & Παπάνας, Ν. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1339788 · Cited by 7
Impact of adding semaglutide in a person with type 1 diabetes: A case report
Sofrà, D., & Beer, S. (2019) · Diabetes Updates · doi:10.15761/du.1000128 · Cited by 6
Individualized diabetes care: Lessons from the real-world experience
Khor, X. Y., Pappachan, J. M., & Jeeyavudeen, M. S. (2023) · World Journal of Clinical Cases · doi:10.12998/wjcc.v11.i13.2890 · Cited by 13
Qiu, L., Ling, P., Yang, D., Luo, S., Zheng, X., Liang, H., Yuan, Y., Liang, G., Xu, W., Yao, B., et al. (2020) · Journal of Diabetes · doi:10.1111/1753-0407.13025 · Cited by 8
Ruddiman, K. R., Bartfield, J. K., & Hirsch, I. B. (2025) · Obesity · doi:10.1002/oby.70033 · Cited by 10
Garg, S. K., Aktürk, H. K., Garg, S., Beck, R. W., Bellini, N. J., Bjornstad, P., Carlson, A. L., Carroll, J., Close, K., Block, C., et al. (2026) · Diabetes Technology & Therapeutics · doi:10.1177/15209156261449879 · Cited by 8
Self-citationUse of GLP-1 Receptor Agonists for the Management of Type 1 Diabetes: A Pediatric Perspective
Nevo-Shenker, M., & Shalitin, S. (2024) · Hormone Research in Paediatrics · doi:10.1159/000541228 · Cited by 9
Saeed, Z. I., Aktürk, H. K., Aleppo, G., Kruger, D. F., Levy, C. J., Mader, J. K., Sherr, J. L., & Shah, V. N. (2024) · Clinical Diabetes · doi:10.2337/cd24-0067 · Cited by 8
Rebelos, E., Anastasiou, I. A., Tentolouris, N., Karagiannis, T., Τσάπας, Α., Ferrannini, E., & Liakos, A. (2025) · HORMONES · doi:10.1007/s42000-025-00704-9 · Cited by 8
The Evolution of Insulin Administration in Type 1 Diabetes
Pinnaro, C. T., & Tansey, M. (2021) · Journal of Diabetes Mellitus · doi:10.4236/jdm.2021.115021 · Cited by 9
The double burden: Navigating type 1 diabetes and obesity
Steenackers, N., Feldman, A., Mathieu, C., Rosen, J., Söderberg, J. A. E., Al‐Ozairi, E., le Roux, C. W., & der Schueren, B. V. (2024) · Clinical Obesity · doi:10.1111/cob.12645 · Cited by 10
Self-citationAn up-to-date evaluation of sotagliflozin for the treatment of type 1 diabetes
Chatzopoulos, G., & Τζιόμαλος, Κ. (2020) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2020.1793961 · Cited by 7
Noninsulin Therapies in Management of Type 1 Diabetes
Saeed, Z. I., Ambalavanan, J., Rayan, M. N., Patadia, P., & Shah, V. N. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.06.027 · Cited by 7
Metadata
- Authors
- Mathieu, C., Zinman, B., Hemmingsson, J. U., Woo, V., Colman, P., Christiansen, E., Linder, M., Bode, B., & for the ADJUNCT ONE Investigators
- Affiliations
- Universitair Ziekenhuis Leuven (BE)
- Mount Sinai Hospital (CA)
- Capio St. Görans Hospital and the Karolinska Institute, Stockholm, Sweden
- Health Sciences Centre (CA)
- The Royal Melbourne Hospital (AU)
- Novo Nordisk (Denmark) (DK)
- Atlanta Diabetes Associates (US)
- Corresponding author
- Mathieu, Chantal
- ORCID
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2016-08-09
- Volume
- 39
- Issue
- 10
- Pages
- 1702-1710
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2514658869
- Cited by
- 347
- References
- 26
- Citations by year
- 2026: 52 · 2025: 56 · 2024: 49 · 2023: 28 · 2022: 23 · 2021: 28 · 2020: 34 · 2019: 27 · 2018: 26 · 2017: 17 · 2016: 7
- FWCI
- 25.77
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Diabetes Care (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- Funders
- Novo Nordisk A/S (NN9211-3919)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Diabetes and associated disorders
- Keywords
- liraglutide, type 1 diabetes, insulin therapy, glycemic control, HbA1c, insulin dose reduction, weight loss, GLP-1 receptor agonists, adjunctive therapy, drug safety, hypoglycemia, nausea, gastrointestinal adverse effects, drug discontinuation
- MeSH terms
- Liraglutide, Adult, Diabetes Mellitus, Type 1, Double-Blind Method, Drug Therapy, Combination, Female, Glycated Hemoglobin, Humans, Hypoglycemic Agents, Injections, Subcutaneous, Insulin, Male, Middle Aged, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.